From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Is it double or quits time for Haleon shareholders?

By Chris Bailey | Wednesday 21 September 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


As I observed yesterday, “some GSK plc (GSK) shareholders have sold their Haleon (HLN) spin-off shares and some have not”. I belong in the latter group on the basis that yesterday’s half one numbers are a classic double or quits moment. After having the opportunity to listen to the conference call yesterday, what am I going to do with my position in one of the world's largest consumer health brands businesses given the range of oral health, vitamins, minerals and supplements (VMS), pain relief and digestive health product exposures the company has.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 10:13:03